Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 1998

View Archived Issues

Antipsychotic drug trifluoperazine inhibits growth of mycobacterial isolates

Potent, broad-spectrum cephalosporin antibiotics in the pipeline at Roche

Fast track designation granted for FGN-1 in APC

Abbott completes acquisition of Murex

FDA requests additional analysis of Exelon before U.S. approval

Mylan announces copromotion agreement

INVICORP approved for launch in Denmark

NeXstar initiates second part of MiKasome phase II trial and reports preliminary findings

Italian launch for Prograf announced

Cyclacel licenses novel drug delivery technology from CNRS

Lilly describes serotonergic agents for treating obesity, CNS disorders

Centrally acting muscarinic agents discovered at American Home Products

Neurocrine Biosciences takes over clinical development of benzodiazepine

World's first brain cell transplant performed in stroke patient

TSL-225, a dipeptide inhibitor of dipeptidyl peptidase IV

CR-2945, a promising new anxiolytic agent in preclinical testing

NIH finds new selective ligands for studying P2X1 purinoceptors

New semisynthetic macrolide antibiotics designed by Pliva

Mitsui Toatsu describes potent, long-acting and orally bioavailable antipsychotic agents

Indolocarbazoles for prostate disorders jointly developed by Cephalon and Kyowa Hakko

Preliminary evidence of antidepressant effect for igmesine, a sigma ligand

Company Profile: Amur

ID Biomedical and Mitsubishi Chemical sign distribution agreement

M-100907 improves positive and negative symptoms and is well tolerated in schizophrenics

Clinical evaluation of AlloMune transplantation system begins

Orally active gastric antisecretory agents synthesized and evaluated at Daiichi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...